UK Expansion For GW Pharma

The UK’s Telegraph newspaper reports

It grows several tons of specially-modified cannabis plants a year – which have had the chemicals that result in a high genetically edited out – in British Sugar’s 44-acre greenhouse in Norfolk. It then processes and purifies the plant material in the UK to make medicines, mostly for export to the massive US market.

We’re proud to be a UK company. We do all our manufacturing in the UK and we are scaling upAdam George, GW Pharma

GW has one approved medicine, an oral spray called Sativex for treating the muscle spasticity associated with the condition multiple sclerosis.

It is hoping for regulatory approval in the US next year for sister cannabis-derived products for treating types of epilepsy, after positive results in clinical trials.

Adam George, UK managing director for GW, said the firm was expanding in Britain to meet anticipated demand for the epilepsy treatment should it get the green light. GW plans to invest £50m in capital funding over the next three years and to recruit 70 new staff. The expansion comes off the back of hiring 100 staff over the past 12 months, taking its UK headcount to 400.

Mr George said: “We’re proud to be a UK company. We do all our manufacturing in the UK and we are scaling up, ready to commercialise (the epilepsy product) next year.”

Cannabis Law Report Has Been Publishing Legal, Professional & Regulated
Cannabis News Daily Since 2016 – All For Free

We want to carry on providing the important cannabis sector
news for free for all our readers.

Costs are rising to produce Cannabis Law Report and we’d like to ask you,
our readers, for a small donation.


Primary Sponsor

New: Free USA Cannabis Case Law Search – New Cases Daily

Directory Categories

Sponsor – aBizinaBox

Top Marijuana Blog
%d bloggers like this: